PMID- 30451154
OWN - NLM
STAT- MEDLINE
DCOM- 20190925
LR  - 20221207
IS  - 2040-2058 (Electronic)
IS  - 1359-6535 (Linking)
VI  - 23
IP  - Suppl 2
DP  - 2018
TI  - Expert opinion on managing chronic HCV infection in patients with type 2 diabetes 
      mellitus.
PG  - 11-21
LID - 10.3851/IMP3255 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has been identified as an extrahepatic 
      manifestation of chronic HCV infection. Conversely, in the context of chronic HCV 
      infection, T2DM can accelerate the course of HCV-induced liver disease leading to 
      increased risk of fibrosis, cirrhosis and hepatocellular carcinoma. The presence 
      of T2DM negatively impacts the efficacy of interferon-based antiviral therapy, 
      but real-world data with high-efficacy direct-acting antiviral therapies suggest 
      high viral clearance rates in T2DM patients. In HCV-infected individuals, viral 
      eradication is associated with a reduced risk of de novo T2DM in non-diabetic 
      patients and beneficial metabolic changes in patients with T2DM, highlighting the 
      importance of antiviral treatment and physician awareness of this association.
FAU - Adinolfi, Luigi Elio
AU  - Adinolfi LE
AD  - Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, 
      Universita degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
FAU - Jacobson, Ira
AU  - Jacobson I
AD  - NYU Langone Health, New York, NY, USA.
FAU - Bondin, Mark
AU  - Bondin M
AD  - AbbVie, Inc., Chicago, IL, USA.
FAU - Cacoub, Patrice
AU  - Cacoub P
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR 7211, and 
      Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France.
AD  - INSERM, UMR_S 959, Paris, France.
AD  - CNRS, FRE3632, Paris, France.
AD  - AP-HP, Groupe Hospitalier Pitie-Salpetriere, Department of Internal Medicine and 
      Clinical Immunology, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Antivir Ther
JT  - Antiviral therapy
JID - 9815705
RN  - 0 (Antiviral Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
CIN - Antivir Ther. 2019;24(2):147-149. PMID: 30835253
MH  - Antiviral Agents/*therapeutic use
MH  - Blood Glucose/drug effects
MH  - Carcinoma, Hepatocellular/*drug therapy/etiology/pathology/virology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/prevention & 
      control/virology
MH  - Disease Management
MH  - Drug Combinations
MH  - Expert Testimony
MH  - Glycated Hemoglobin/antagonists & inhibitors/metabolism
MH  - Hepatitis C, Chronic/complications/*drug therapy/pathology/virology
MH  - Humans
MH  - Insulin Resistance
MH  - Liver/drug effects/metabolism/pathology/virology
MH  - Liver Cirrhosis/*drug therapy/etiology/pathology/virology
MH  - Liver Neoplasms/*drug therapy/etiology/pathology/virology
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2018/11/20 06:00
MHDA- 2019/09/26 06:00
CRDT- 2018/11/20 06:00
PHST- 2018/06/27 00:00 [accepted]
PHST- 2018/11/20 06:00 [entrez]
PHST- 2018/11/20 06:00 [pubmed]
PHST- 2019/09/26 06:00 [medline]
AID - 10.3851/IMP3255 [doi]
PST - ppublish
SO  - Antivir Ther. 2018;23(Suppl 2):11-21. doi: 10.3851/IMP3255.